Showing results (231-240 of 264) with videos related to
Sort By:
Pageof 27
Journal of the American Academy of Dermatology|March 6, 2026
Hormonal Contraceptives: Part I- Formulations and Physiological Effects on the SkinAmit Singal, Marcia S Driscoll, Jane M Grant-Kels, et al.Archives of Dermatological Research|April 5, 2021
Patient-reported outcome measures for patients with nail conditions: a systematic review of the psychometric evidenceRakhshan Kamran, Leah Algu, Cameron F Leveille, et al.Cutis|November 3, 2025
Approach to Diagnosing and Managing Implantation MycosesDallas J Smith, Conceição Maria Pedrozo E Silva de Azevedo, Ahmed Fahal, et al.Mycoses|January 12, 2024
Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agentsAditya K Gupta, Boni Elewski, Warren S Joseph, et al.Journal of Drugs in Dermatology : JDD|January 6, 2026
Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian ParticipantsShari R Lipner, Aditya K Gupta, Tracey C Vlahovic, et al.Journal of the American Academy of Dermatology|June 21, 2025
Part II. Dermatologic Manifestations Associated with Treatment of Patients with Kidney DiseaseAmit Singal, Shawn E Cowper, Christine J Ko, et al.Clinical, Cosmetic and Investigational Dermatology|November 2, 2023
Development and Validation of a Patient-Reported Outcome Measure for Fingernail and Toenail Conditions: The NAIL-QAnne F Klassen, Charlene Rae, Maureen O'Malley, et al.Journal of Drugs in Dermatology : JDD|October 12, 2021
Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the USShari R Lipner, Warren S Joseph, Tracey C Vlahovic, et al.American Journal of Clinical Dermatology|March 18, 2024
Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal ResistanceRachel C Hill, Avrom S Caplan, Boni Elewski, et al.Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|October 25, 2024
Prescribing of clotrimazole-betamethasone dipropionate, a topical combination corticosteroid-antifungal product, for Medicare part D beneficiaries, United States, 2016-2022Dustin W Currie, Avrom S Caplan, Kaitlin Benedict, et al.Pageof 27